KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNTech SE (BNTX) Operating Expenses (2018 - 2025)

BioNTech SE's Operating Expenses history spans 8 years, with the latest figure at -$784.6 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 1.61% to -$784.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.0 billion, a 1.74% increase, with the full-year FY2025 number at -$3.0 billion, up 0.57% from a year prior.
  • Operating Expenses hit -$784.6 million in Q4 2025 for BioNTech SE, up from -$802.0 million in the prior quarter.
  • Over the last five years, Operating Expenses for BNTX hit a ceiling of -$299.7 million in Q2 2021 and a floor of -$813.6 million in Q2 2024.
  • Historically, Operating Expenses has averaged -$600.6 million across 5 years, with a median of -$653.9 million in 2022.
  • Biggest five-year swings in Operating Expenses: plummeted 131816999.25% in 2021 and later increased 12.79% in 2025.
  • Tracing BNTX's Operating Expenses over 5 years: stood at -$460.3 million in 2021, then plummeted by 39.56% to -$642.4 million in 2022, then decreased by 17.58% to -$755.4 million in 2023, then fell by 2.22% to -$772.2 million in 2024, then dropped by 1.61% to -$784.6 million in 2025.
  • Business Quant data shows Operating Expenses for BNTX at -$784.6 million in Q4 2025, -$802.0 million in Q3 2025, and -$709.5 million in Q2 2025.